Description
The AFS98 monoclonal antibody specifically recognizes CD115 which is also known as Colony stimulating factor 1 Receptor (CSF-1R), Macrophage colony-stimulating factor 1 receptor (M-CSFR), or c-fms. This type I transmembrane glycoprotein is a receptor tyrosine kinase (RTK) that is encoded by Csf1r which belongs to the Ig superfamily. CD115 (CSF-1R) is comprised of an extracellular ligand-binding domain that is followed by a single transmembrane segment and a split intracellular tyrosine kinase domain. This receptor is expressed on monocytes, macrophages, dendritic cells, osteoclasts, and their precursors. Colony-stimulating factor 1 (CSF-1), also known as Macrophage colony-stimulating factor (M-CSF), binds to and signals through CD115 (CSF-1R) homodimers which undergo tyrosine autophosphorylation. The activated receptors transduce intracellular signals resulting in cytoskeletal reorganization and gene expression involved in the proliferation, differentiation, and survival of CSF-1-responding cells. Through CD115 (CSF-1R), CSF-1 regulates the release of proinflammatory cytokines and other mediators from macrophages and plays a role in the bone resorption activity of osteoclasts. Interleukin-34 (IL-34) is another ligand for CD115 (CSF-1R) that can induce similar, as well as, some different biological responses by target cells that express this receptor.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to BD CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD CompBead to ensure that BD CompBeads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. Alexa Fluor® is a registered trademark of Life Technologies Corporation.
10. BD Horizon Brilliant Violet 711 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
11. Cy is a trademark of GE Healthcare.
